文章：

前列腺导管内癌的临床管理

Clinical Management of Intraductal Carcinoma of the Prostate

原文发布日期：25 April 2024

DOI: 10.3390/cancers16091650

类型: Article

开放获取: 是

英文摘要：

Intraductal carcinoma of the prostate (IDC-P) has emerged as a distinct entity with significant clinical implications in prostate cancer (PCa) management. Despite historically being considered an extension of invasive PCa, IDC-P shows unique biological characteristics that challenge traditional diagnostic and therapeutic settings. This review explores the clinical management of IDC-P. While the diagnosis of IDC-P relies on specific morphological criteria, its detection remains challenging due to inter-observer variability. Emerging evidence underscores the association of IDC-P with aggressive disease and poor clinical outcomes across various PCa stages. However, standardized management guidelines for IDC-P are lacking. Recent studies suggest considering adjuvant and neoadjuvant therapies in specific patient cohorts to improve outcomes and tailor treatment strategies based on the IDC-P status. However, the current level of evidence regarding this is low. Moving forward, a deeper understanding of the pathogenesis of IDC-P and its interaction with conventional PCa subtypes is crucial for refining risk stratification and therapeutic interventions.

摘要翻译： 

前列腺导管内癌（IDC-P）作为一种具有独特临床意义的独立实体，在前列腺癌（PCa）诊疗中日益受到关注。尽管历史上曾被视为浸润性前列腺癌的延伸，IDC-P展现出独特的生物学特性，对传统诊断和治疗模式提出了挑战。本文综述了IDC-P的临床管理现状。虽然IDC-P的诊断依赖于特定的形态学标准，但由于观察者间存在差异，其检测仍具挑战性。最新证据表明，IDC-P与侵袭性病程及不良临床结局密切相关，且这种关联存在于前列腺癌的各个阶段。然而，目前尚缺乏针对IDC-P的标准化管理指南。近期研究提示，在特定患者群体中应考虑辅助治疗及新辅助治疗，以期根据IDC-P状态改善预后并制定个体化治疗策略，但相关证据等级仍较低。未来，深入理解IDC-P的发病机制及其与传统前列腺癌亚型的相互作用，对于完善风险分层和治疗干预至关重要。

原文链接：

Clinical Management of Intraductal Carcinoma of the Prostate